Rapid Dose Therapeutics Corp (DOSE) AI Stock Analysis

• Market Cap: C$18.46M
• Dividend Yield: N/A
• Average Volume (3M): 36.09K
• Price to Earnings (P/E): ―
• Beta (1Y): -0.46
• Revenue Growth: 95.76%
• EPS Growth: 22.56%
• Country: CA
• Employees: N/A
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): >-0.01
• Shares Outstanding: 131,886,760
• 10 Day Avg. Volume: 35,351
• 30 Day Avg. Volume: 36,089
• PEG Ratio: -0.38
• Price to Book (P/B): -5.82
• Price to Sales (P/S): 18.01
• P/FCF Ratio: -8.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 41 Neutral
• Price Target: C$0.13 ▼(-4.29% Downside)

The score is primarily weighed down by weak financial performance (persistent large losses, negative equity, and ongoing cash burn). Technicals add caution with the stock trading below major moving averages and negative MACD, while valuation is difficult to justify with a negative P/E and no dividend yield data.

Positive Factors

Proprietary delivery platform

Owning a quick-dissolve oral thin-film technology is a durable competitive asset: it enables recurring formulation partnerships and white‑label opportunities across pharma and consumer health, supporting predictable licensing or manufacturing revenue as adoption broadens.

Revenue trend improvement

Revenue improvements since 2023 show early commercial traction. While absolute sales are small, a consistent upward trend validates product-market fit and supports the case that incremental sales could leverage fixed development and manufacturing costs over the next several quarters.

Product gross margins

A ~30% gross margin indicates the underlying product economics can support profitability as scale increases. With higher volume and fixed-cost absorption, these unit economics could translate to meaningful operating leverage over a multi-quarter horizon.

Negative Factors

Negative shareholders' equity

A deficit equity position and notable debt raise solvency and refinancing risk. Negative equity constrains strategic flexibility, increases default or covenant risk, and likely forces dilutive or costly financing if cash needs persist over the coming months.

Ongoing cash burn

Sustained negative operating and free cash flow means the company cannot self‑fund growth or operations long term. Continued burn will require external capital, increasing dilution risk and potentially delaying commercialization or R&D investments critical for scale.

Deep negative profitability

Severely negative operating and net margins show the business is far from break‑even; fixed and overhead costs outpace revenues. Achieving durable profitability will require significant revenue expansion or structural cost reductions over multiple quarters.

Rapid Dose Therapeutics Corp Business Overview & Revenue Model

Company Description

Rapid Dose Therapeutics Corp., a life sciences company, provides drug delivery technologies designed to enhance outcomes and quality of lives in Canada. The company offers QuickStrip/PharmaStrip, an oral fast-dissolving drug delivery system to rapidly release active ingredients into the blood stream, such as pharmaceuticals, emulsified oils, and over-the-counter medicines; QuickStrip energy to deliver energizing caffeine; QuickStrip B12 to deliver vitamin B12 in the system; and QuickStrip sleep that delivers melatonin in the system. The company also provides product innovation, production, and consultation services to the nutraceutical, cannabis healthcare, and pharmaceutical manufacturing industries. It has a research partnership program with McMaster University for developing biopolymer compositions that can offer enhanced drug delivery performance when formulated in oral dissolvable thin films, as well as for developing orally delivered vaccine candidate for COVID-19. Rapid Dose Therapeutics Corp. is based in Burlington, Canada.

How the Company Makes Money

Rapid Dose Therapeutics Corp generates revenue primarily through the sale and licensing of its QuickStrip™ technology. The company partners with pharmaceutical, nutraceutical, and cannabis companies to incorporate QuickStrip™ into their product lines, earning income from manufacturing agreements and royalties. Additionally, Rapid Dose may engage in joint ventures or strategic collaborations to expand its application range and market penetration, further boosting its revenue streams.

Rapid Dose Therapeutics Corp Financial Statement Overview

Summary

Financial statements indicate high risk: small TTM revenue ($2.78M) with modest growth, but very weak profitability (EBIT margin ~-111%, net margin ~-157%), negative shareholders’ equity (~-$6.65M) with meaningful debt (~$8.28M), and ongoing cash burn (TTM operating cash flow ~-$0.91M; free cash flow ~-$3.46M).

Income Statement

TTM (Trailing-Twelve-Months) revenue is small ($2.78M) with modest growth (+5.9%), but profitability remains very weak: gross margin is ~30% while operating results are deeply negative (EBIT margin ~-111%) and the company is still reporting large net losses (net margin ~-157%). Annual results show revenues have generally improved since 2023, but losses have persisted every year and remain sizable relative to sales, highlighting an ongoing challenge to scale profitably.

Balance Sheet

The balance sheet is strained, with negative shareholders’ equity in the most recent periods (TTM equity about -$6.65M) alongside meaningful debt (TTM total debt about $8.28M). Total assets are relatively low (~$3.79M TTM), and the combination of rising leverage and a deficit equity position increases financial risk and reduces flexibility, particularly if additional funding is needed.

Cash Flow

Cash generation remains weak with negative operating cash flow in TTM (about -$0.91M) and materially negative free cash flow (about -$3.46M), indicating ongoing cash burn. While free cash flow improved versus the prior period (positive growth rate), the company is still not self-funding operations, and the gap between cash outflows and profitability suggests continued reliance on external capital.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2022	Dec 2020
Income Statement
Total Revenue	2.78M	2.09M	1.02M	1.75M	718.30K	755.20K
Gross Profit	829.37K	1.18M	563.41K	1.34M	372.40K	699.85K
EBITDA	-2.62M	-3.93M	-3.02M	-7.59M	-2.92M	-987.00K
Net Income	-4.37M	-5.40M	-4.31M	-8.49M	-3.81M	-1.80M
Balance Sheet
Total Assets	3.79M	1.63M	1.89M	3.07M	2.25M	3.83M
Cash, Cash Equivalents and Short-Term Investments	109.16K	20.72K	161.06K	34.44K	27.59K	70.26K
Total Debt	8.28M	2.61M	2.45M	1.43M	1.61M	2.06M
Total Liabilities	10.43M	6.84M	5.04M	2.82M	4.92M	5.41M
Stockholders Equity	-6.65M	-5.21M	-3.16M	251.56K	-2.67M	-1.58M
Cash Flow
Free Cash Flow	-3.46M	-1.15M	-2.29M	-3.04M	-863.92K	-1.63M
Operating Cash Flow	-906.04K	-1.15M	-2.29M	-3.00M	-863.92K	-1.62M
Investing Cash Flow	-2.55M	-5.74K	0.00	1.85M	0.00	-9.12K
Financing Cash Flow	3.49M	1.01M	2.43M	1.13M	856.53K	1.65M

Rapid Dose Therapeutics Corp Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.14
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:DOSE, the sentiment is Negative. The current price of 0.14 is below the 20-day moving average (MA) of 0.14, below the 50-day MA of 0.15, and below the 200-day MA of 0.18, indicating a bearish trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 47.62 is Neutral, neither overbought nor oversold. The STOCH value of <0.01 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:DOSE.

Rapid Dose Therapeutics Corp Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
BLAB	47 Neutral	C$16.23M	-2.00	―	―	-3.93%	-575.24%
BCT	44 Neutral	C$35.28M	-0.08	-409.25%	―	―	62.01%
HEM	44 Neutral	C$16.96M	-3.09	―	―	―	-24.89%
DOSE	41 Neutral	C$18.46M	-4.19	―	―	95.76%	22.56%

Rapid Dose Therapeutics Corp Corporate Events

Rapid Dose Therapeutics Pays Convertible Note Interest in Shares

Rapid Dose Therapeutics Corp. will issue 362,708 common shares to holders of its secured convertible notes to satisfy approximately $47,154 in quarterly interest accrued as of December 31, 2025, with issuance expected by January 15, 2026. The interest payment in shares stems from an amended and restated note financing originally completed in 2023, under which the company extended the maturity of $3.08 million in promissory notes and associated warrants to November 30, 2026; the notes carry an 18% annual interest rate payable in stock at the Canadian Securities Exchange quarter-end closing price, a structure that preserves cash but dilutes existing shareholders while providing continued support from noteholders.

The most recent analyst rating on (TSE:DOSE) stock is a Hold with a C$0.13 price target. To see the full list of analyst forecasts on Rapid Dose Therapeutics Corp stock, see the TSE:DOSE Stock Forecast page.

Rapid Dose Therapeutics Extends Convertible Notes Maturity Date

Rapid Dose Therapeutics Corp. announced an extension of the maturity date for its secured convertible notes, originally set to mature on November 30, 2025, to November 30, 2026. This extension involves noteholders agreeing to new terms, including an increased interest rate from 12% to 18% per annum and an extension fee payable in common shares. The company also plans to issue common shares to satisfy accrued interest, with securities subject to a hold period. This move is part of a related party transaction involving company insiders and is exempt from certain regulatory requirements.